anonymous
Guest
anonymous
Guest
FYI Layoffs Will be inevitable! Rybelsus is underperforming and look for more layoffs coming as early as September and especially last quarter of the year!
WRONG!!FYI Layoffs Will be inevitable! Rybelsus is underperforming and look for more layoffs coming as early as September and especially last quarter of the year!
Quit trying to scare folks! Not Happening buddy!
FYI Layoffs Will be inevitable! Rybelsus is underperforming and look for more layoffs coming as early as September and especially last quarter of the year!
Unfortunately, this is true. However, it has nothing to do with Rybelsus. It’s always been part of the plan. Ultimate goal is a singular sales force (no specialty) with 820 HCS (Health Care Specialist). We’ll be there by 2025 at the latest. You heard it here first.
It is that time of year. I am sure we will
Keep laying off that is the way Novo rolls these days. They shouldn’t keep rehiring for all the positions that have been vacant. But the DBM are to worried about losing there job. So guess what they keep hiring . Why don’t we put a hiring freeze in place oh wait we already are where we want to be and we have already trimmed the fat that was last years line but wait now it’s the same time of year what will they say recent headwinds in the Buisness I am sure it will be some line that we think we won’t understand. Listen up people who may being lured to come over to fill these vacancy please spare yourself and stay where you are this company is a huge flight risk at this point with one molecule yes one molecule.
Unfortunately, this is true. However, it has nothing to do with Rybelsus. It’s always been part of the plan. Ultimate goal is a singular sales force (no specialty) with 820 HCS (Health Care Specialist). We’ll be there by 2025 at the latest. You heard it here first.
Hate to agree with you and can't believe we are talking about this again, but generic Victoza will hurt as will the combo agonist if it is approved. One of the regional directors stated, when referring to that product, that it will be a 'major market event'.
Generic Victoza won't come to the market till holidays 2023. Company will be pushing hard in 2022 and 2023 to switch everyone to O and R. Not a reason for layoffs.
Tirzepatide has nice data but look how long it takes to convince these dumb docs about GLP1. They won't get gip. Cardiologists won't care for it no CV. We got sema 2 dose coming prob before Lilly drug gets approved.
But Lilly will rebate and contract circles around us so it'll make it on every formulary.
Prob not layoffs but "restructuring" everyone to obesity. Rybelsus ship has sunk for now.